Tag: European

European Cannabis Round-Up: New Figures Show Healthy Growth In Czech Medical Cannabis, Goodbody Health Sells CBD Facility, & French Study Reveals Ageing Cannabis Users

Czechia’s Medical Cannabis

AS Czechia races ahead with plans to launch a fully regulated adult-use cannabis market, with the potential to beat Germany to the punch, new data suggests its medical cannabis market is also experiencing healthy growth.

In January 2022, Czechia made significant changes to its medical cannabis framework making it much easier for patients to access products.

This has helped drive an increase in patient numbers of almost 25{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c} in the 11 months to November 2022, compared to full-year 2021.

In 2021, patient numbers grew by 22.5{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c} to 4601, in the first 11 months of 2022 patient numbers grew to 5744.

According to newly released data from Czechia’s State Agency For Medical Cannabis, there was also a significant jump in November, with patient numbers topping 2000 for the first time in a single month.

This was reflected in the number of grams of medical cannabis issued, increasing nearly 10{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c} month-on-month and nearly 30{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c} when compared to January 2022.

Earlier this year CEO of the Czech patients association KOPAC, Hana Vágnerová, told Prohibition Partners that the most significant barrier to market growth was that ‘only specialised doctors who register for providing medical cannabis can treat patients and this number stands at 150 as of February 2022, or about one such specialist per 100,000 people’.

The government’s new data suggests that by November this had increased by 13{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c} to 168, and could now stand at over 200.

While January’s changes to legislation have helped drive a steady increase in the market, other factors including a single domestic cultivator, restrictive licensing and continued restrictions on who can prescribe are hampering further expansion.

Period	No. prescriptions issued	No.of grams issued	No. patients	No. of prescribing doctors
January	2055	11607.63	1721	151
February	1872	10526.19	1580	152
March	2275	12362.23	1816	153
April	2088	11620.87	1743	144
May	2401	13202.4	1973	150
June	2347	13758.58	1961	156
July	1959	12391.75	1694	156
August	2221	13282.76	1886	159
September	2364	14236.64	1985	163
October	2311	13606.73	1993	162
November	2591	14911.67	2194	168
Total	24484	141507,45	5744	212

Voyager Life Expands Into Poland

Scottish CBD firm Voyager Life has announced the £1.5m acquisition of a CBD extraction and manufacturing facility in Poland from its UK-based CBD stablemate Goodbody Health.

On December 16 Voyager announced that it planned to take ‘full operational control’ of the facility on January 1 2023.

The GMP certified facility is understood to have been bought by Stillcanna (which subsequently merged with Goodbody) for £13m in 2019.

Its sale at nearly a tenth of its original price marks the latest move away from the CBD industry from Goodbody, which has pivoted its focus increasingly towards COVID and blood testing initiatives in recent months.

While there was no indication that Goodbody planned to stop selling its range of CBD products, it said in a parallel statement that ‘the levels of CBD sales by Goodbody Health were insufficient justification for meeting the costs of running a full extraction plant and the level of management input.’

Meanwhile Voyager says it now plans to begin manufacturing its CBD products in Poland, alongside producing other plant-based products like essential oils and cold-pressed hemp seed oil.

The company says this will turn it into a vertically integrated, pan-European business, giving it control over its supply chain from extraction to manufacture and retail.

It will also see Voyager acquire the shares of Goodbody’s subsidiaries Sativa Wellness Poland and Olimax.

Voyager will pay £0.5m in cash, and the further £1m in convertible loan notes ‘subject to regulatory approval’ being granted by Polish authorities.

To fund the acquisition, Voyager has reportedly raised around £550k from new investors, existing shareholders and its CEO Nick Tulloch and Non-Executive Chairman Eric Boyle.

According to Voyager, the aforementioned directors have ‘irrevocably agreed to subscribe for £200k of the £550k.’

However, these investments are understood to take the pair over the threshold of the ‘Takeover Code’, which stipulates any shareholders which carry more than 30{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c} of the voting rights must make a cash offer to purchase the rest of the shares.

Shareholders will be asked to vote on whether to waive this obligation in a ‘forthcoming general meeting’.

Alongside this, Voyager intends to issue nearly 3m new ordinary shares at a price of 12p per share on Aquis, raising proceeds of £0.35m, to partially fund the acquisition.

French Study Sheds Light On Cannabis Usage

A new trends study of 23,661 adults aged 18 to 64, conducted by the French Observatory of Drugs and Addictive Trends (OFDT), revealed that the age of cannabis users had increased significantly over the past 30 years.

According to the study, published on December 19, the average age of current cannabis users has risen from 25 in 1992 to 32 in 2021.

For those under 25 however, usage has been falling since 2017. Experimentation dropped 5.5{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c} between 2017 and 2021, while regular usage fell by 2.1{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c} to 6.3{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c}.

Conversely, the percentage of 45 to 54-year-olds who say they consumed cannabis at least once a month grew from 2.9{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c} to 3.4{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c} since 2017, while the number of 55 to 64-year olds who had consumed cannabis during the year also grew from 1.6{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c} to 2.5{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c}.

General consumption remained relatively stable, with 47.3{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c} of those surveyed stating they had used cannabis in their lifetime.

Cannabis continued to be the most widely used illicit substance in France, with 10.6{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c} of adults stating they had consumed it in the last year, a level similar to that in 2017.

More regular consumption appeared to be falling however, with those consuming cannabis 10 or more times a month dropping from 3{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c} in 2017 to 1.7{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c} in 2021, and those consuming daily dropping from 3.6{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c} to 2.2{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c} over the same period.

December 21, 2022

CBD hemp skin care brand Fuss Pot launches in France and eyes European expansion

Established in 2007, Cann Worldwide was active in the health-related hashish place and also operated a well being food items division as nicely. Its move into energetic pores and skin treatment with the Fuss Pot brand aimed to consider the electric power of hashish, via CBD [cannabidiol] and hemp actives, into magnificence.

Fuss Pot had developed two distinct pores and skin treatment ranges: a hemp-primarily based line concentrating on ageing and a CBD-primarily based line for fix. Both equally traces featured cleansers, serums, creams and entire body oils.

Offered on the internet via its web site, the manufacturer had kickstarted with the launch of its ‘ageless’ hemp pores and skin treatment line and would enter France this thirty day period and Australia in August with the range. The start of its CBD variety was on the horizon.

Setting up ‘support’ and ‘community’ all around the model

“We’re brand name-new globally. We did a compact generation run late very last year, just to get us into the area, but we will be formally kicking off in Europe,” stated Toni Cohen, marketing manager at Cann World-wide.

The brand name was starting up in France wherever it had a strong community, such as a formulation companion, and would then look to grow even more into Europe after it had constructed up “the aid and the group all over the product”, Cohen explained.

Speaking to CosmeticsDesign-Europe at Cosmoprof All over the world Bologna again in April, she said there experienced already been strong curiosity from the Uk, the Nordics, Canada and the US, but enlargement would come about slowly and gradually. “We really do not want to rush we want to do it nicely.”

Tackling the patchwork of CBD and hemp regulations

As the manufacturer expanded, Cohen explained it would have to navigate the patchwork of differing laws throughout the world, especially in Europe, but with two diverse traces, which includes a hemp-based assortment that faced much less legislative hurdles, Fuss Pot was self-confident it could extend reach very well. Cann World-wide also had widespread knowledge in doing the job in these fields, she explained, which would help transferring forward.

“Cann International, the dad or mum organization, has been in the cannabis and hemp place for many years (…) so, this is our heritage.

“…We actually fully grasp that hemp seed oil, which is our anti-ageing vary, is just as efficient in what it’s striving to do as the CBD fixing selection. So, we’re not heading to lose out. We think equally ranges are incredible, and if your marketplace accepts it, then – superb. We have set the science into the two,” she reported.

D2C engagement with retail ‘visual appeal’

Even though the model would continue to promote immediate-to-consumer (D2C), Cohen said Fuss Pot obviously experienced “visual appeal” for merchandising in much more standard bricks and mortar settings. Its ranges ended up packed in matte black UV protecting glass and utilized sustainable cardboard with vibrant styles as secondary packaging. These investments also intended the brand name would under no circumstances be mass sector, sitting down additional in the mid-to-high quality end of skin care.

“So that people can study and buy at their very own advantage, D2C is massive for us. But we are also performing with suppliers who are aligned with what we’re making an attempt to do and the consumer we’re trying to goal.”

And that client, she explained, ended up men and women searching for “natural skin treatment merged with helpful outcomes”.

“It’s not just about being all-natural and organic, which is obviously quite vital for the modern day customer, but it’s also about generating absolutely sure that it operates. So, we have the investigate and facts guiding both equally hashish and hemp from our guardian organization, but then are also functioning with our French formulator to make certain all the components we use have some sort of scientific or scientific qualifications for success,” she reported.

Further than CBD and hemp?

Requested if Cann World was seeking into other cannabinoids for Fuss Pot, Cohen reported: “To a certain diploma, for the reason that of the regulatory atmosphere, a ton of exploration has been lacking on some of all those other types. As I reported, it is actually important for us that the science and facts is there. So, as it gets to be out there – and we’re investing in this space ourselves, in terms of the terpenes side of issues and other cannabinoids – we surely will go on to investigate, innovate and look into as the knowledge becomes available.”

July 12, 2022
CBD of Denver (OTCMKTS: CBDD) Investors Looking for Big Week Ahead as European CBD Innovator Marks Expansion into German Medical Cannabis Market

CBD of Denver (OTCMKTS: CBDD) has been under accumulation in recent weeks and recently broke north of its trading range. The stock had fallen to lows of $0.0016 from highs near $0.04 in early 2021, and the cannabis market looks ripe for a rally as there are 8 states with Marijuana legalization measures on the ballet including Texas, Oklahoma, South Dekota, Ohio, North Dekota, Nebraska, Missouri, Maryland, Iowa, and Arkansas.

CBDD hit the OTC in November 2018 and Microcapdaily reported on it at the time, stating in our article from November 16 “CBDD is a publicly traded company listed on OTC Markets and traded under the stock symbol CBDD. The Company is currently developing innovative CBD products and related social networking. CBDD is the new ticker for VGMI. The Company is led by new CEO Nicholas Sprung, a serial entrepreneur who used to be CEO of a Ski Company with an ambitious vision to make CBD of Denver a leader in the booming CBD space. The Company has established its principal corporate office located at 4610 South Ulster Street, Suite 150, Denver, CO 80237, where it has rented office space.

CBD of Denver (OTCMKTS: CBDD) is a Distributor of CBD and Cannabis flower and a producer of a full line of CBD oil and unique products sold in Switzerland and throughout Europe. CBD of Denver, Inc. is focused on using equity to acquire profitable Swiss assets at attractive valuations to create value for all our shareholders and is driven by a passion to improve lives and strengthen communities by unleashing the full potential of cannabis. Through our Rockflowr brands we have built a very strong European customer base by focusing on top quality products and meaningful customer relationships.

Earlier this year CBDD reported it filed audited financial statements for fiscal year 2021 on April 15, 2022 reporting a record $23.5 million in revenue and net income of $0.33 million. Management credits a fast growing market for its success and first profitable year. According to CBD of Denver CEO Paul Gurney: “While our internal momentum continues to grow, the market itself is providing increasing tailwinds. Just this week, Swiss authorities greenlighted a recreational usage pilot in the city of Basel to begin over the summer. As this trend potentially spreads across Switzerland, and ultimately across Europe, CBD of Denver is ideally positioned to capitalize on the rapidly evolving opportunities,” added Gurney. “I want to thank our shareholders for their continued support. I firmly believe we are on a great trajectory and look forward to reporting on our ongoing successes.”

While fiscal year 2021 financial results were exceptional the Company was negatively impacted in Q1, 2022, due to the reintroduction of COVID controls across Europe and pricing pressure on CBD flower. These trends have already reversed, and the Company’s April revenue nearly surpassed the entire first quarter’s revenue as prices began to stabilize. CBD of Denver generated $908,086 revenue in the first three months of 2022, with a net loss of $314,248 mainly on an inventory write down of $102,856. CEO Paul Gurney said “On the surface, the numbers don’t tell the full story and should be viewed in context. While revenues at 3.5{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c} margins don’t usually result in overall profitability, my mandate is to transform this business from a commodity trader into a higher-margin, multi-pronged, health and wellness powerhouse in Europe and Asia.”

$CBDD #Switzerland #Europe #London #Asia #CBD #Cannabis @Rockflowr1 #BeMoreMellow https://t.co/BFU4ybkpJJ

— Riz🇺🇸 (@84mongoose) June 3, 2022

To Find out the inside Scoop on CBDD Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

The Company recently acquired 100{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c} of Mellow, a CBD ecommerce distribution platform and technology company, with capabilities in the UK, Europe, and Asia, for an undisclosed sum. The acquisition is expected to close in the second quarter of 2022. With operations in Asia, Mellow gives CBDD an entrance into the rapidly evolving CBD markets in the fast-growing Asia Pacific region. The Mellow technology stack will accelerate the Company’s plans to become the go-to name for cannabis across all parts of the value chain in international markets. his acquisition will combine technology and retail e-commerce distribution alongside manufacturing and supply chain infrastructure to create a turnkey solution for the CBD industry across Europe. According to CBDD management “Mellow is also the leading multi-channel distribution partner of choice for globally minded CBD and Hemp brands in Asia too, with our own physical store network and ecommerce channels. This is a global play.”

The Company recently expanded into the German medical cannabis market with the hiring of Bijan Hezarkhani to lead CBD of Denver’s growth in this fast growing European market. Bijan has extensive experience in the cannabis industry, including building out a medical cannabis franchise in Germany. He was the business development manager for Khiron Life Sciences for the last three years, visiting doctors and pharmacies in Germany to build Khiron’s medical cannabis business. Previously, he spent time at Canopy Growth as a business analyst covering Europe. Bijan will be the head of the Company’s medical cannabis sales in Germany and will be based in Frankfurt.

Germany officially approved medical cannabis in 2017. Germany is the largest medical cannabis market in Europe at 15 tonnes annually and generated approximately US$300 million of revenue in 2021. According to Forbes Magazine, over a million patients in Germany will have access to medical cannabis by 2024, with the German medical market worth €7.7 billion by 2028. The German market appears to be moving closer to adult-use legalization, a market estimated at 400 tonnes annually, making it critical to have the infrastructure in place in country. With 83 million people, Germany is the most attractive market in Europe for cannabis.

On May 26 CBDD announced mellow has signed an agreement with UK luxury CBD consumer brand OTO to act as their distribution partner in Asia. OTO, headquartered in London, is a premium positioned consumer CBD wellness brand, specializing in offering sophisticated products at the luxury end of the industry price spectrum. Mellow aims to provide the OTO brand experience through its mellow Asia division, which is operated out of the Hong Kong market, and which already operates a network of physical retail stores under the mellow banner as well as an eCommerce site

CBDD CEO said Paul Gurney said: “We are extremely excited to welcome the OTO brand to the mellow portfolio of brands in Hong Kong. This agreement will combine retail and technology/e-commerce distribution to enable mellow to continue the great work that the OTO team have achieved in other markets, and in doing so, will position OTO as the leading luxury CBD and wellness brand in the Asian markets. There is no other company present in the industry in Hong Kong with offering close to that of OTO. We are very pleased to be able to make this announcement, and we have much more in store ahead.”

Microcapdaily reported on CBDD in November 2020 in the $0.002 level right before the stock skyrocketed to over $0.03 per share in December. We stated in our article “CBD of Denver Inc. (OTCPINK: CBDD) is making an explosive move up the charts after the Company announced record revenues of $5,963,820.00 with gross profits of $484,666.00 for the 3rd quarter ended September 30, 2020. CBDD is an emerging player in the booming global CBD oil and CBD consumer health market which is expected to reach USD $123.2 billion by 2027, expanding at a CAGR of 25.6{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c} over the forecast period. It’s easy to see why penny stock speculators are so bullish on CBDD; the Company’s subsidiary Rockflowr GmbH is quickly emerging as one of the leading wholesale companies for CBD in Switzerland. Rockflowr sources its hemp flower from the United States in large quantities and its distribution has grown to more than 7 countries in Europe. Rockflowr GmbH generated the bulk of CBDD revenues.”

$CBDD #CBDD

We are very pleased to be able to make this announcement, and we have much more in store ahead,” said Paul Gurney, CEO of CBD of Denver.

CBD of Denver Signs Licensing Agreement with UK Luxury CBD Brand OTO https://t.co/yxYdOgZTPz

— A10Vet (@A10_Vet1) May 26, 2022

For More on CBDD Subscribe Right Now!

Currently trading at a $31 million market valuation CBD of Denver has come a long way since we first reported on it in 2018, when the Company as nothing more than an ambitious vision. CBDD had a stellar year in 2021 reporting a record $23.5 million in revenue and net income of $0.33 million. While fiscal year 2021 financial results were exceptional the Company was negatively impacted in Q1, 2022, due to the reintroduction of COVID controls across Europe and pricing pressure on CBD flower. These trends have already reversed, and the Company’s April revenue nearly surpassed the entire first quarter’s revenue as prices began to stabilize. CBDD has been under accumulation in recent weeks and recently broke north of its trading range. The stock had fallen to lows of $0.0016 from highs near $0.04 in early 2021, and the cannabis market looks ripe for a rally as there are 8 states with Marijuana legalization measures on the ballet including Texas, Oklahoma, South Dekota, Ohio, North Dekota, Nebraska, Missouri, Maryland, Iowa, and Arkansas. Microcapdaily gave the heads up on CBDD in November 2020 when the stock was $0.002 right before it ran to over $0.03 in December 2020. We will be updating on CBDD when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with CBDD.

Disclosure: we hold no position in CBDD either long or short and we have not been compensated for this article.

June 6, 2022
New CBD Regulatory Framework Published by France’s Ministry of Health Opens New Commercial Opportunities for RAMM Pharma’s European Operations

TORONTO, Jan. 05, 2022 (Globe NEWSWIRE) — RAMM Pharma Corp., which includes its wholly owned subsidiaries, the “Enterprise” or “RAMM”) (CSE: RAMM), a leader in plant-derived cannabinoid pharmaceutical solutions, applauds France’s new regulatory framework for the sale of cannabidiol (“CBD”). Pursuant to the recent announcement, France will enable the utilization of the total hemp plant, including flowers and leaves, for the industrial creation of extracts by setting the THC limit to .3{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c} in the two bulk extracts and final merchandise, devoid of any limitation for other cannabinoids. The French Wellness Ministry’s ordinance, posted on Friday 31 December, 2021 in the Journal Officiel, offers a new regulatory framework for the sale and trading of hemp extracts.

The ordinance is posted at the following connection: https://www.legifrance.gouv.fr/jorf/id/JORFTEXT000044793213.

Even further protection is out there at the pursuing url: https://www.lemonde.fr/societe/post/2021/12/31/la-france-clarifie-sa-place-sur-le-cbd-en-interdisant-la-vente-de-fleurs-et-de-feuilles-de-chanvre_6107809_3224.html.

“2022 begins with breakthrough information as it eventually clarifies and opens the market for extracts and CBD in France. This opens a scenario that has been very long awaited in Europe and is envisioned to give a domino impact for other European Member States to observe fit”, stated Jack Burnett, Chief Govt Officer, RAMM Pharma Corp.

According to the new ordinance, which enhances the Decree of 22 August 1990, “bouquets and leaves of the types [Cannabis sativa L.] can be harvested, imported or used for the industrial production of extracts”. This is an epochal action forward for the European Market mainly because, on one particular hand, it represents the comprehensive implementation of the indications derived by the European Courtroom of Justice’s posture in the popular Kanavape situation and, on the other hand, it is issued by a European Union chief member condition, France, that experienced so considerably taken a strongly restrictive stance on hemp and its derivatives. France is the second biggest state in the EU powering Germany with a inhabitants of more than 68 million men and women. The overall EU CBD sector worth was € 1.6 billion in 2020 and is projected to expand to €8.7 billion in 2030 (EU Hemp Sector Report, HIS Markit).

Through its 100{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c} ownership of Canapar Corp., RAMM is very well positioned to become a person of Europe’s greatest vertically built-in hashish organizations. Canapar’s point out-of-the-art extraction facility positioned in Sicily, Italy is the most significant in Europe and has been personalized designed to develop active compounds to be applied in large-top quality pharmaceutical, wellness, meals and beauty items from its 1,000-hectare natural and organic hemp creation and processing platform.

RAMM’s strategic foothold in Europe also gives developing distribution alternatives for RAMM’s portfolio of internationally registered cannabis-dependent solutions manufactured at its condition-of-the-artwork GMP accredited facility in Montevideo Uruguay which is preferably positioned in just near proximity to an international airport and other export hubs. This 36,000 sq.ft. facility characteristics committed hashish and health-related product or service laboratories along with packaging capabilities and storage/distribution facilities.

About RAMM Pharma Corp.
RAMM Pharma is a leader in the field of cannabinoid pharmacology and product or service formulation for cannabis-based prescription drugs and other hashish-based mostly solutions with a special and diversified global production and profits system. The company operates an founded pharmaceutical and healthcare solution company in Uruguay that has formulated several medically registered and accepted plant-derived cannabinoid pharmaceutical solutions that have been licensed for sale and/or compassionate use in several Latin American nations. RAMM also has a pipeline of new merchandise, together with registered hashish-centered nourishment and specialized veterinary solutions, in many stages of acceptance and enhancement, which are manufactured at the firm’s state-of-the-artwork, good-manufacturing-practice-accredited hashish formulation facility in Montevideo, Uruguay.

In Europe, RAMM’s vertically built-in functions are primarily based in Ragusa, Italy, and contain: a hemp cultivation platform a significant extraction and processing facility (in the ultimate levels of commissioning) to generate an extensive line of cannabidiol formulations, APIs (active pharmaceutical elements) and wellness merchandise.

RAMM Pharma features wholly owned subsidiaries Canapar Corp., Medic Plast SA, Yurelan SA, Glediser SA and RAMM Pharma Holdings Corp.

Extra information and facts about the Enterprise is readily available at www.rammpharma.com.

For further more data, make sure you get hold of:

Antonio Caruso
Chief Operating Officer of Canapar, SRL
+39 331 188 5927
[email protected]

Cautionary Take note Relating to Forward-Seeking Details

This information launch contains “forward-on the lookout details“ and “forward-searching statements“ (collectively, “forward hunting statements“) in the this means of the applicable Canadian securities laws. All statements, other than statements of historic simple fact, are ahead-looking statements and are based mostly on expectations, estimates and projections as at the day of this information launch. Any statement that includes discussions with regard to predictions, anticipations, beliefs, options, projections, targets, assumptions, potential occasions or effectiveness (normally but not often working with phrases these kinds of as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or versions of this kind of words and phrases or stating that sure steps, situations or success “may” or “could”, “would”, “might” or “will” be taken to take place or be accomplished) are not statements of historical actuality and might be forward-hunting statements. In this information release, ahead on the lookout statements relate, amid other matters, the Company’s techniques and goals, and upcoming growth options.

These ahead-on the lookout statements are based on realistic assumptions and estimates of administration of the Enterprise at the time these statements had been manufactured. True future benefits may perhaps differ materially as forward-hunting statements require recognized and mysterious challenges, uncertainties and other components which may induce the real final results, performance or achievements of the Organization to materially differ from any foreseeable future benefits, functionality or achievements expressed or implied by these forward-searching statements. Such factors, among the other issues, include: the predicted rewards to RAMM of France’s new regulatory framework for the sale of CBD fluctuations in basic macroeconomic ailments fluctuations in securities markets anticipations regarding the dimensions of the Uruguayan, Latin American, and global professional medical and leisure cannabis markets and switching purchaser habits the ability of the Organization to effectively reach its company objectives ideas for expansion political and social uncertainties lack of ability to get sufficient insurance plan to cover dangers and hazards and the existence of laws and restrictions that could impose restrictions on cultivation, generation, distribution and sale of hashish and cannabis linked items in Uruguay or internationally and staff relations. Whilst the ahead-looking statements contained in this news launch are centered on what administration of the Business believes, or believed at the time, to be fair assumptions, the Business can’t assure shareholders that genuine benefits will be constant with these kinds of forward-looking statements, as there may well be other aspects that trigger success not to be as predicted, approximated or meant. Visitors should really not place undue reliance on the ahead-wanting statements and details contained in this news release. The Corporation assumes no obligation to update the ahead-hunting statements of beliefs, thoughts, projections, or other aspects, should really they modify, besides as essential by law.

No stock exchange, securities commission or other regulatory authority has permitted or disapproved the information contained herein.

January 6, 2022